This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...

At what was supposed to be a hearing to discuss PBM reform, some in Congress veered off into discussions about Medicaid and ...

Unlike some other spending cuts, Medicaid cuts will have direct impact on people who voted for Republicans in November 2024, ...

But major cuts to federal for Medicaid are a likely outcome of the $1.5-$2 trillion in spending cuts over the next 10 years that the Republican-backed budget resolution calls for.